公司新闻(英文)
May 9, 2018 / 6:31 PM / 9 months ago

BRIEF-Cellectar Granted Orphan Drug Designation For CLR 131

1 分钟阅读

May 9 (Reuters) - Cellectar Biosciences Inc:

* CELLECTAR GRANTED ORPHAN DRUG DESIGNATION FOR CLR 131 TO TREAT RHABDOMYOSARCOMA Source text for Eikon: Further company coverage:

我们的标准：汤森路透“信任原则”
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below